The Use of Janus Kinase Inhibitors for Lichen Planus: An Evidence-Based Review

Author:

Abduelmula Abrahim1ORCID,Bagit Ahmed2,Mufti Asfandyar3ORCID,Yeung Katie C.Y.4ORCID,Yeung Jensen3567

Affiliation:

1. Faculty of Medicine, University of Western Ontario, London, Ontario, Canada

2. Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

3. Division of Dermatology, Department of Medicine, University of Toronto, Ontario, Canada

4. Faculty of Medicine, Queen’s University, Kingston, Ontario, Canada

5. Women’s College Research Institute, Women’s College Hospital, Toronto, Ontario, Canada

6. Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

7. Probity Medical Research, Waterloo, Ontario, Canada

Abstract

Background Lichen Planus (LP) is a dermatological disorder characterized by violaceous papules that affect the cutaneous region, nails, scalp, and mucous membranes. Current molecular and clinical studies point to the Janus Kinase-signal transducer and activator of transcription (JAK-STAT) pathway as a potential effector of LP pathology. Objective This systematic review summarizes the current reported literature outcomes for patients receiving JAK inhibitors to treat LP. Methods MEDLINE and Embase were searched on 16 October, 2022, and 15 original articles were included, with 56 LP patients. Results (mean age: 54.5 years, range: 26-81 years, male: 26.8%). The treatment outcomes were included for the following JAK inhibitors: tofacitinib ( n = 30), baricitinib ( n = 16), ruxolitinib ( n = 12), and upadacitinib ( n = 2). Patient outcomes were classified into complete resolution, partial resolution, and no resolution. Patients achieving complete resolution represented 25% ( n = 4/16) in the baricitinib group, 10% ( n = 3/30) in the tofacitinib group, 16.7% ( n = 2/12) in the ruxolitinib group, and 100% (2/2) in the upadacitinib group. Partial resolution patients represented 31.3% ( n = 5/16) of baricitinib patients, 60% ( n = 18/30) of tofacitinib patients, and 83% ( n = 10/12) of ruxolitinib patients. 43.8% ( n = 7/16) of baricitinib patients and 10% ( n = 9/30) of tofacitinib patients had no resolution of lesions. Conclusion This review also highlights the significance of utilizing a uniform outcome measure for LP, as it aids in reporting more generalizable results, reduces reporting bias, and ultimately lead to improved clinical outcomes for LP patients.

Publisher

SAGE Publications

Subject

Dermatology,Surgery

Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3